Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Systems Modeling

Systems Modeling

Dynamic, mechanistic models of biology

Our Systems modeling services help derive mechanistic, translational insights from mathematical models of biological processes at the subcellular levels.

The modeling and simulations can be used for the following:

  • Disease models: Mechanism of action, virtual knock-in/knock-out simulations, phenotypes
  • Toxicity Assessment: Simulate the time and dose-dependent effect of a drug to establish the safety window; Heptox platform for hepatoxicity
  • PK/PD models: Establish dose-concentration-response relationships and simulate time-effect courses; determine in vivo efficacy and first-in-human dose
  • Clinical Study design: Compartmental/non-compartmental models, adaptive trial design
  • Bioprocess simulations: Manufacturing process simulations, scale-up and real-time optimization of operating conditions

Effect of a protease inhibitor on bilirubin levels in normal and Gilbert’s syndrome patients

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details